Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults

Authors

  • Ryuzo Ohno MD,

    Corresponding author
    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    • First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumaicho, Showaku, Nagoya, Japan
    Search for more papers by this author
  • Masami Hirano,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Kuniyuki Imai,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Katsuo Koie,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Tadashi Kamiya,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Hiroshi Nishiwaki,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Junzo Ishiguro,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Tadaaki Uetani,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Fujio Sako,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Kazuo Imamura,

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author
  • Kazumasa Yamada

    1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    2. Department of Medicine, Aichi Kenshoku Hospital, Nagoya, Japan
    Search for more papers by this author

Abstract

Thirty-seven adults with acute myelogenous leukemia (AML) were treated with a combination of daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) for remission induction. Twenty-three of 37 patients (62.2%) achieved complete remission, three, partial remission and 11, failure. Patients with prior therapy responded as well as patients without it. The median survival time of the patients who received DCMP for their initial remission induction therapy was 10.3 months and that of the patients who obtained complete remission was 17 months. Complete remission occurred in 21 out of 28 patients (75%) less than 40 years old but in only two out of nine patients (22.2%) more than 40 years old. The most common toxic effects were severe myelosuppression and liver function abnormalities. DCMP therapy is an effective remission induction chemotherapy for adults with AML.

Ancillary